Adaptimmune: Evasion is futile

Adaptimmune Ltd. believes its autologous T cell therapies with high affinity T cell receptors can treat diseases that would otherwise evade the immune system. Its lead programs are for cancer and HIV.

T cells are responsible for recognizing and removing infected or diseased cells. T cells become activated when a T cell receptor (TCR) on the cell surface binds a foreign peptide antigen presented by a specific subtype of human leukocyte antigen (HLA) on the surface of another cell. Activated T cells then mount an immune response against the target cell...